Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

DCTH vs TNDM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DCTH Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 5–4 Matrix Metrics)

DCTH Overall Winner 6-Pillar Tally: DCTH 5 – 1 TNDM Matrix Metrics: DCTH 5 – 4 TNDM

As of Nov 16, 2026, Delcath Systems Inc (DCTH) is the stronger overall head-to-head candidate over Tandem Diabetes Care, Inc. (TNDM) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). DCTH carries a Unified Composite Score of 35.9/100 (SELL) at $19.68 (N/M Forward P/E, 5.2% operating margin), whereas TNDM carries 37.1/100 (SELL) at $19.11 (N/M Forward P/E, -2.4% operating margin).

  • Composite vs. Pillar Nuance: While TNDM currently prints a higher short-term Unified Composite Score (37.1/100 SELL vs. DCTH 35.9/100 SELL), DCTH captures the overall institutional head-to-head verdict (5–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (5.2% vs. -2.4% operating margin) and revenue trajectory (+70.7% vs. +13.8% YoY).
  • Defensive Composite Rating Caution: Although DCTH compares more favorably head-to-head, both DCTH (35.9/100 SELL) and TNDM (37.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DCTH vs TNDM
DCTH NASDAQ Head-to-Head Winner
Delcath Systems Inc
Surgical & Medical Instruments & Apparatus
$19.68
-4.23% 1D
Market Cap $743.8M
TTM Revenue $110M
Forward P/E N/M
Beta / 30D Vol 1.63β · 131% Vol
Unified Composite Score
35.9 / 100 SELL
Tech 50.0 Fund 38.0 Flow 60.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 69
RSI-14: 68.9 · SMA20: $16.43 · SMA50: $15.96
TNDM NASDAQ
Tandem Diabetes Care, Inc.
Surgical & Medical Instruments & Apparatus
$19.11
-4.78% 1D
Market Cap $1.2B
TTM Revenue $1.08B
Forward P/E N/M
Beta / 30D Vol 1.15β · 88% Vol
Unified Composite Score
37.1 / 100 SELL
Tech 51.0 Fund 37.0 Flow 57.0 Mom 31.1
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 55
RSI-14: 55.3 · SMA20: $18.35 · SMA50: $17.39

6-Pillar Scorecard Institutional Category Breakdown (DCTH 5 – 1 TNDM)

Columns: Metric · DCTH · TNDM
1. Valuation Multiples TNDM
Forward P/E N/M N/M
Trailing P/E 133.6x 55.2x
PEG Ratio 1.60x N/M
EV / Revenue 6.3x 1.8x
2. Growth & Scale DCTH
Revenue Growth (YoY) +70.7% +13.8%
Earnings Growth (YoY) +750.0% -37.0%
TTM Revenue (USD) $110M $1.08B
Market Cap $743.8M $1.2B
3. Profitability & Quality DCTH
Gross Margin 87.6% 56.6%
Operating Margin 5.2% -2.4%
Net Profit Margin 6.0% -4.6%
Return on Equity (ROE) 5.4% -36.7%
4. Balance Sheet & Cash Flow DCTH
Cash Generation (TTM) $20M -$71M
Cash Flow Margin 18.3% -6.6%
Net Cash / Leverage $53M Net Cash $664M Net Debt (5.45x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DCTH
Options Structure Phase BREAKOUT CONSOLIDATION
Current IV / %ile 109.3% (43rd %ile) 77.8% (10th %ile)
Put/Call OI Skew 0.11x (Call-Skewed) 0.04x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Neutral ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat DCTH
OpEx & R&D Intensity 82.4% of Rev ($91M) 59.0% of Rev ($635M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DCTH (5) vs TNDM (4)
Institutional Metric DCTH TNDM Criterion Row Edge
Market Capitalization
Scale
$743.8M $1.2B Larger Scale TNDM
Trailing P/E Ratio
Valuation
133.6x 55.2x Lower Multiple TNDM
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+70.7% +13.8% Higher Growth DCTH
Operating Margin (TTM)
Profitability
5.2% -2.4% Higher Margin DCTH
Net Profit Margin
Profitability
6.0% -4.6% Higher Margin DCTH
Return on Equity (ROE)
Capital Efficiency
5.4% -36.7% Higher ROE DCTH
52-Week Range Position
Momentum
80% ($8–$23) 39% ($12–$30) Stronger Trend DCTH
Beta / 30D Volatility
Risk Regime
1.63β · 131% Vol 1.15β · 88% Vol Lower Realized Risk TNDM
Unified Institutional Score
Composite Signal
35.9 / 100 (SELL) 37.1 / 100 (SELL) Higher Composite TNDM
Trailing 12M Revenue (USD)
Operating Scale
$110M $1.08B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
87.6% 56.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.60x PEG · 6.3x EV/Rev N/M PEG · 1.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$20M ($53M Net Cash) -$71M ($664M Net Debt (5.45x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DCTH +22.1 pp
DCTH: +39.77% · TNDM: +17.67%
3M Horizon DCTH +36.2 pp
DCTH: +16.73% · TNDM: -19.47%
6M Horizon DCTH +36.22 pp
DCTH: +77.46% · TNDM: +41.24%
1Y Horizon DCTH +119.56 pp
DCTH: +128.57% · TNDM: +9.01%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period DCTH Revenue TNDM Revenue DCTH Op. Margin TNDM Op. Margin Margin Leader
FY2018 N/A $180M N/A -24.3% TNDM
FY2019 N/A $360M N/A -4.6% TNDM
FY2020 N/A $500M N/A -1.6% TNDM
FY2021 $0M $700M -690.0% 3.2% TNDM
FY2022 $0M $800M -1245.1% -11.6% TNDM
FY2023 $0M $750M -1849.0% -31.2% TNDM
FY2024 $40M $940M -33.4% -10.5% TNDM
FY2025 $90M $1.01B 0.8% -18.5% DCTH

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DCTH BREAKOUT
66d in phase · OBV ACCUMULATION
Current IV 109.3%
IV Percentile 43rd %ile
Put/Call OI Skew 0.11x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact DCTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TNDM CONSOLIDATION
68d in phase · OBV ACCUMULATION
Current IV 77.8%
IV Percentile 10th %ile
Put/Call OI Skew 0.04x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact TNDM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DCTH Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $743.8M market capitalization and 5.2% operating margin.
OpEx & R&D Reinvestment 82.4% of Rev ($91M)
90D Engineering Disclosures 0 Published
TNDM Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $1.2B market capitalization and -2.4% operating margin.
OpEx & R&D Reinvestment 59.0% of Rev ($635M)
90D Engineering Disclosures 0 Published

Investor FAQ DCTH vs TNDM Key Questions & Quantitative Answers

As of Nov 16, 2026, Delcath Systems Inc (DCTH) is the stronger overall head-to-head candidate over Tandem Diabetes Care, Inc. (TNDM) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). DCTH carries a Unified Composite Score of 35.9/100 (SELL) at $19.68 (N/M Forward P/E, 5.2% operating margin), whereas TNDM carries 37.1/100 (SELL) at $19.11 (N/M Forward P/E, -2.4% operating margin). Composite vs. Pillar Nuance: While TNDM currently prints a higher short-term Unified Composite Score (37.1/100 SELL vs. DCTH 35.9/100 SELL), DCTH captures the overall institutional head-to-head verdict (5–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (5.2% vs. -2.4% operating margin) and revenue trajectory (+70.7% vs. +13.8% YoY). Defensive Composite Rating Caution: Although DCTH compares more favorably head-to-head, both DCTH (35.9/100 SELL) and TNDM (37.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

DCTH leads the Growth & Scale pillar: DCTH posts +70.7% YoY revenue growth and +750.0% YoY earnings growth on $110M TTM revenue (87.6% gross margin, 5.2% operating margin), compared with TNDM at +13.8% YoY revenue growth and -37.0% YoY earnings growth on $1.08B TTM revenue (56.6% gross margin, -2.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), DCTH cumulative revenue shifted +125.0% while TNDM shifted +461.1%. In operating R&D and SG&A reinvestment, DCTH deploys 82.4% of Rev ($91M) (0 90-day corporate R&D disclosures) versus 59.0% of Rev ($635M) (0 disclosures) for TNDM.

TNDM screens cheaper on headline valuation multiples. DCTH trades at N/M Forward P/E, 133.6x Trailing P/E, 1.60x PEG, and 6.3x EV/Revenue (18.3% FCF margin), whereas TNDM trades at N/M Forward P/E, 55.2x Trailing P/E, N/M PEG, and 1.8x EV/Revenue (-6.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DCTH (5.4% ROE) versus TNDM (-36.7% ROE) capital efficiency.

In options market volatility and institutional positioning, DCTH carries 109.3% implied volatility (43rd %ile, Balanced (25th–60th %ile)), a 0.11x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.63β · 131% Vol realized risk). By comparison, TNDM carries 77.8% implied volatility (10th %ile, Compressed (<25th %ile)), a 0.04x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.15β · 88% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.